Accession Number:

ADA433911

Title:

Selenium is a Chemotherapeutic Agent for the Treatment of Prostate Cancer

Descriptive Note:

Annual rept. 5 Jan 2004-4 Jan 2005

Corporate Author:

STANFORD UNIV CA SCHOOL OF MEDICINE

Personal Author(s):

Report Date:

2005-02-01

Pagination or Media Count:

16.0

Abstract:

A large body of data suggests that selenium supplementation may be used as a chemopreventative strategy to reduce the risk of prostate cancer. In spite of this, little is known about the use of selenium as a cancer therapy. The inorganic form of selenium, selenite, undergoes thiol-dependent reduction to selenide, which supplies selenium for the synthesis of selenoproteins. At lower concentrations, the major effects of selenite are related to its role as a micronutrient. However, at higher concentrations, selenite may become toxic. Excessive selenite metabolism depletes cells of the primary intracellular antioxidant, glutathione, and generates superoxide. The net effect of the metabolism of selenite is a profound alteration in the cellular redox status and generation of potentially lethal reactive oxygen species. The authors characterized the response of androgen-dependent LAPC-4 prostate cancer cells, as well as patient-matched pairs of normal and malignant prostate cells to selenite. Selenite-induced growth inhibition and apoptosis were correlated with changes in Bcl-2 family member expression, altered intracellular GSH status, and MnSOD expression. They also examined the ability of selenite to sensitize prostate cancer cells to gamma irradiation. The primary goal of this proposal was to generate preclinical data supporting the concept that selenite might be useful as a novel chemotherapeutic agent alone or in combination with radiation therapy to treat prostate cancer.

Subject Categories:

  • Medicine and Medical Research
  • Food, Food Service and Nutrition
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE